The use of beta blockers within 2 months of randomization
Patients actively listed for transplantation at time of entry into the study or anticipated to undergo heart transplantation, interventional catheterization, or corrective cardiac surgery during the 7 months following entry into the study
Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator, and/or significant cardiac conduction defects, e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning pacemaker is in place
Uncorrected obstructive or severe regurgitant valve disease, nondilated cardiomyopathy, or significant systemic ventricular outflow obstruction
Known renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units) unresponsive to vasodilator agents such as oxygen, nitroprusside, or nitric oxide
History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma) requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators
Renal, hepatic, gastrointestinal, or biliary disorder that could impair absorption, metabolism or excretion of orally administered medication
Concurrent terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s) which, in the opinion of the investigator, could preclude participation or survival
Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus
Unwillingness or inability to cooperate, or for the parents or guardians to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation in the study
Pregnancy or possible pregnancy at time of randomization, or female of child bearing potential who are lactating, or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)
Use of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug (the longer period will apply)
History of drug sensitivity or allergic reaction to alpha-blockers or beta-blockers
Use of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists
Hospital admission for protein losing enteropathy or plastic bronchitis within 3 months of randomization
Active and/or chronic protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis).
Hypoalbuminemia defined as serum albumin <2.0g/dL
Renal dysfunction defined as serum creatinine >2.0mg/dL
Hepatic dysfunction defined as serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age),
Significant anemia or polycythemia defined as hemoglobin >18gm/dL or hemoglobin <7gm/dL
Severely elevated serum BNP defined as BNP>300pg/ml

NCT02946892_exc_T1
Drug
beta blockers
NCT02946892_exc_T2
Temporal
within 2 months of randomization
NCT02946892_exc_T3
Reference_point
randomization
NCT02946892_exc_T4
Observation
listed for transplantation
NCT02946892_exc_T5
Procedure
transplantation
NCT02946892_exc_T6
Temporal
at time of entry into the study
NCT02946892_exc_T7
Reference_point
entry into the study
NCT02946892_exc_T8
Mood
anticipated to undergo
NCT02946892_exc_T9
Procedure
heart transplantation
NCT02946892_exc_T10
Procedure
interventional catheterization
NCT02946892_exc_T11
Procedure
corrective cardiac surgery
NCT02946892_exc_T12
Temporal
during the 7 months following entry into the study
NCT02946892_exc_T13
Reference_point
entry into the study
NCT02946892_exc_T14
Scope
heart transplantation, interventional catheterization, or corrective cardiac surgery
NCT02946892_exc_T15
Qualifier
symptomatic
NCT02946892_exc_T16
Qualifier
Sustained
NCT02946892_exc_T17
Condition
ventricular dysrhythmias
NCT02946892_exc_T18
Qualifier
uncontrolled by drug therapy
NCT02946892_exc_T19
Procedure
drug therapy
NCT02946892_exc_T20
Drug
drug
NCT02946892_exc_T21
Scope
Sustained or symptomatic
NCT02946892_exc_T22
Device
implantable defibrillator
NCT02946892_exc_T23
Qualifier
controlled by d e use of an implantable defibrillator,
NCT02946892_exc_T24
Scope
uncontrolled by drug therapy or the use of an implantable defibrillator
NCT02946892_exc_T25
Qualifier
significant
NCT02946892_exc_T26
Condition
cardiac conduction defects
NCT02946892_exc_T27
Condition
d degree o  block
NCT02946892_exc_T28
Condition
3rd degree AV block
NCT02946892_exc_T29
Condition
sick sinus syndrome
NCT02946892_exc_T30
Scope
significant cardiac conduction defects
NCT02946892_exc_T31
Scope
2nd degree or 3rd degree AV block, or sick sinus syndrome
NCT02946892_exc_T32
Negation
unless
NCT02946892_exc_T33
Qualifier
functioning
NCT02946892_exc_T34
Device
pacemaker
NCT02946892_exc_T35
Qualifier
Uncorrected
NCT02946892_exc_T36
Condition
tructive or ve disease, n
NCT02946892_exc_T37
Qualifier
severe
NCT02946892_exc_T38
Condition
regurgitant valve disease
NCT02946892_exc_T39
Condition
nondilated cardiomyopathy
NCT02946892_exc_T40
Qualifier
significant
NCT02946892_exc_T41
Condition
systemic ventricular outflow obstruction
NCT02946892_exc_T42
Condition
renovascular hypertension
NCT02946892_exc_T43
Condition
pulmonary hypertension
NCT02946892_exc_T44
Mood
evidence of
NCT02946892_exc_T45
Measurement
pulmonary vascular resistance
NCT02946892_exc_T46
Value
> 6 Wood units
NCT02946892_exc_T47
Scope
pulmonary vascular resistance > 6 Wood units
NCT02946892_exc_T48
Scope
evidence of pulmonary hypertension
NCT02946892_exc_T49
Qualifier
unresponsive to vasodilator agents
NCT02946892_exc_T50
Drug
vasodilator agents
NCT02946892_exc_T51
Drug
oxygen
NCT02946892_exc_T52
Drug
nitroprusside
NCT02946892_exc_T53
Drug
nitric oxide
NCT02946892_exc_T54
Scope
oxygen, nitroprusside, or nitric oxide
NCT02946892_exc_T55
Scope
renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units)
NCT02946892_exc_T56
Observation
History
NCT02946892_exc_T57
Temporal
current
NCT02946892_exc_T58
Mood
clinical evidence of
NCT02946892_exc_T59
Qualifier
moderate-to-severe
NCT02946892_exc_T60
Qualifier
fixed
NCT02946892_exc_T61
Condition
obstructive pulmonary disease
NCT02946892_exc_T62
Qualifier
severe
NCT02946892_exc_T63
Condition
reactive airway diseases
NCT02946892_exc_T64
Condition
asthma
NCT02946892_exc_T65
Scope
reactive airway diseases (e.g., asthma)
NCT02946892_exc_T66
Scope
moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma)
NCT02946892_exc_T67
Scope
History or current
NCT02946892_exc_T68
Procedure
hospitalization
NCT02946892_exc_T69
Mood
requiring
NCT02946892_exc_T70
Temporal
within the past 2 years
NCT02946892_exc_T71
Temporal
currently
NCT02946892_exc_T72
Drug
long-term inhaled bronchodilators
NCT02946892_exc_T73
Reference_point
the past 2 years
NCT02946892_exc_T74
Scope
requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators
NCT02946892_exc_T75
Qualifier
Renal
NCT02946892_exc_T76
Qualifier
hepatic
NCT02946892_exc_T77
Qualifier
gastrointestinal
NCT02946892_exc_T78
Qualifier
biliary
NCT02946892_exc_T79
Condition
disorder
NCT02946892_exc_T80
Scope
Renal, hepatic, gastrointestinal, or biliary
NCT02946892_exc_T81
Condition
impair absorption
NCT02946892_exc_T82
Condition
 abso lism or ex
NCT02946892_exc_T83
Condition
 abso ion of or
NCT02946892_exc_T84
Drug
orally administered medication
NCT02946892_exc_T85
Scope
impair absorption, metabolism or excretion
NCT02946892_exc_T86
Temporal
Concurrent
NCT02946892_exc_T87
Condition
terminal illness
NCT02946892_exc_T88
Condition
severe disease
NCT02946892_exc_T89
Qualifier
other
NCT02946892_exc_T90
Qualifier
active
NCT02946892_exc_T91
Condition
neoplasm
NCT02946892_exc_T92
Scope
active neoplasm
NCT02946892_exc_T94
Procedure
laboratory
NCT02946892_exc_T95
Condition
significant laboratory value(s)
NCT02946892_exc_T96
Measurement
laboratory
NCT02946892_exc_T97
Scope
terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s)
NCT02946892_exc_T98
Condition
Endocrine disorders
NCT02946892_exc_T99
Condition
primary aldosteronism
NCT02946892_exc_T100
Condition
pheochromocytoma
NCT02946892_exc_T101
Condition
hypothyroidism
NCT02946892_exc_T102
Condition
r hyp sm, insuli
NCT02946892_exc_T103
Qualifier
insulin-dependent
NCT02946892_exc_T104
Condition
diabetes mellitus
NCT02946892_exc_T105
Scope
primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus
NCT02946892_exc_T106
Observation
ness or inabi ate, or for
NCT02946892_exc_T107
Observation
inability to cooperate
NCT02946892_exc_T108
Observation
ness or inabi arents or guard onsent, or for
NCT02946892_exc_T109
Observation
 to coop arents or guard onsent, or for
NCT02946892_exc_T110
Observation
ness or inabi arents  to give consent, or fo
NCT02946892_exc_T111
Observation
 to coop arents  to give consent, or fo
NCT02946892_exc_T112
Condition
Pregnancy
NCT02946892_exc_T113
Mood
possible
NCT02946892_exc_T114
Condition
pregnancy
NCT02946892_exc_T115
Temporal
at time of randomization
NCT02946892_exc_T116
Reference_point
time of randomization
NCT02946892_exc_T117
Person
female
NCT02946892_exc_T118
Observation
child bearing potential
NCT02946892_exc_T119
Observation
lactating
NCT02946892_exc_T120
Scope
female of child bearing potential who are lactating
NCT02946892_exc_T121
Observation
sexually active
NCT02946892_exc_T122
Negation
not
NCT02946892_exc_T123
Qualifier
adequate
NCT02946892_exc_T124
Observation
contraceptive precautions
NCT02946892_exc_T125
Device
intrauterine device
NCT02946892_exc_T126
Drug
oral contraceptives
NCT02946892_exc_T127
Temporal
for 3 months prior to entry into the study
NCT02946892_exc_T128
Reference_point
entry into the study
NCT02946892_exc_T129
Scope
intrauterine device or oral contraceptives for 3 months prior to entry into the study
NCT02946892_exc_T130
Scope
not taking adequate contraceptive precautions
NCT02946892_exc_T131
Scope
sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)
NCT02946892_exc_T132
Drug
investigational drug
NCT02946892_exc_T133
Temporal
within 30 days of randomization
NCT02946892_exc_T134
Reference_point
randomization
NCT02946892_exc_T135
Temporal
within 5 half-lives of the investigational drug
NCT02946892_exc_T136
Drug
investigational drug
NCT02946892_exc_T137
Scope
within 30 days of randomization, or within 5 half-lives of the investigational drug
NCT02946892_exc_T138
Observation
History
NCT02946892_exc_T139
Condition
drug sensitivity
NCT02946892_exc_T140
Condition
allergic reaction
NCT02946892_exc_T141
Drug
alpha-blockers
NCT02946892_exc_T142
Drug
beta-blockers
NCT02946892_exc_T143
Scope
alpha-blockers or beta-blockers
NCT02946892_exc_T144
Scope
drug sensitivity or allergic reaction
NCT02946892_exc_T146
Temporal
within two weeks of randomization
NCT02946892_exc_T145
Drug
MAO inhibitors
NCT02946892_exc_T147
Drug
Calcium channel blockers
NCT02946892_exc_T148
Drug
alpha blockers
NCT02946892_exc_T149
Drug
beta blockers
NCT02946892_exc_T150
Drug
disopyramide
NCT02946892_exc_T151
Drug
flecainide
NCT02946892_exc_T152
Drug
encainide
NCT02946892_exc_T153
Drug
moricizine
NCT02946892_exc_T154
Drug
propafenone
NCT02946892_exc_T155
Drug
sotalol
NCT02946892_exc_T156
Drug
beta adrenergic agonists
NCT02946892_exc_T157
Scope
MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists
NCT02946892_exc_T158
Procedure
Hospital admission
NCT02946892_exc_T159
Condition
protein losing enteropathy
NCT02946892_exc_T160
Condition
plastic bronchitis
NCT02946892_exc_T161
Temporal
within 3 months of randomization
NCT02946892_exc_T162
Scope
protein losing enteropathy or plastic bronchitis
NCT02946892_exc_T163
Reference_point
randomization
NCT02946892_exc_T164
Qualifier
Active
NCT02946892_exc_T165
Qualifier
chronic
NCT02946892_exc_T166
Condition
protein losing enteropathy
NCT02946892_exc_T167
Condition
plastic bronchitis
NCT02946892_exc_T168
Drug
inhaled medication
NCT02946892_exc_T169
Scope
protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis)
NCT02946892_exc_T170
Scope
Active and/or chronic
NCT02946892_exc_T171
Condition
Hypoalbuminemia
NCT02946892_exc_T172
Measurement
serum albumin
NCT02946892_exc_T173
Value
<2.0g/dL
NCT02946892_exc_T174
Condition
Renal dysfunction
NCT02946892_exc_T175
Measurement
serum creatinine
NCT02946892_exc_T176
Value
>2.0mg/dL
NCT02946892_exc_T177
Condition
Hepatic dysfunction
NCT02946892_exc_T178
Measurement
serum AST
NCT02946892_exc_T179
Measurement
LT> 3  l
NCT02946892_exc_T180
Value
> 3 times upper limit of normal
NCT02946892_exc_T181
Scope
serum AST and/or ALT
NCT02946892_exc_T182
Value
approximately 120 IU/L
NCT02946892_exc_T184
Scope
serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age)
NCT02946892_exc_T185
Qualifier
Significant
NCT02946892_exc_T186
Condition
anemia
NCT02946892_exc_T187
Condition
polycythemia
NCT02946892_exc_T188
Measurement
hemoglobin
NCT02946892_exc_T189
Value
>18gm/dL
NCT02946892_exc_T190
Measurement
hemoglobin
NCT02946892_exc_T191
Value
<7gm/dL
NCT02946892_exc_T192
Scope
hemoglobin >18gm/dL or hemoglobin <7gm/dL
NCT02946892_exc_T193
Scope
Significant anemia or polycythemia
NCT02946892_exc_T194
Scope
anemia or polycythemia
NCT02946892_exc_T195
Value
Severely elevated
NCT02946892_exc_T196
Measurement
serum BNP
NCT02946892_exc_T197
Measurement
BNP
NCT02946892_exc_T198
Value
>300pg/ml
NCT02946892_exc_T199
Scope
Severely elevated serum BNP
NCT02946892_exc_T200
Scope
BNP>300pg/ml